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Background: The non-availability of clinical trial results contributes to publication bias, diminishing the validity of
systematic reviews and meta-analyses. Although clinical trial registries have been established to reduce non-
publication, the results from over half of all trials registered in ClinicalTrials.gov remain unpublished even 30 months
after completion. Our goals were i) to utilize information available in registries (specifically, the number and sample
sizes of registered unpublished studies) to gauge the sensitivity of a meta-analysis estimate of the effect size and its
confidence interval to the non-publication of studies and ii) to develop user-friendly open-source software to
perform this quantitative sensitivity analysis.
Methods: The open-source software, the R package SAMURAI, was developed using R functions available in the R
package metafor. The utility of SAMURAI is illustrated with two worked examples.
Results: Our open-source software SAMURAI, can handle meta-analytic datasets of clinical trials with two independent
treatment arms. Both binary and continuous outcomes are supported. For each unpublished study, the dataset requires
only the sample sizes of each treatment arm and the user predicted ‘outlook’ for the studies. The user can specify five
outlooks ranging from ‘very positive’ (i.e., very favorable towards intervention) to ‘very negative’ (i.e., very favorable towards
control).
SAMURAI assumes that control arms of unpublished studies have effects similar to the effect across control arms of
published studies. For each experimental arm of an unpublished study, utilizing the user-provided outlook, SAMURAI
randomly generates an effect estimate using a probability distribution, which may be based on a summary effect across
published trials. SAMURAI then calculates the estimated summary treatment effect with a random effects model
(DerSimonian & Laird method), and outputs the result as a forest plot.
Conclusions: To our knowledge, SAMURAI is currently the only tool that allows systematic reviewers to incorporate
information about sample sizes of treatment groups in registered but unpublished clinical trials in their assessment of the
potential impact of publication bias on meta-analyses. SAMURAI produces forest plots for visualizing how inclusion of
registered unpublished studies might change the results of a meta-analysis. We hope systematic reviewers will find
SAMURAI to be a useful addition to their toolkit.
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Clinicians, policy makers, and patients rely on the results
of clinical trials to make informed decisions about health
care. Meta-analyses collate and combine results of clin-
ical trials to provide a quantitative summary of available
evidence regarding a specific clinical question. Unfortu-
nately, the non-publication of trial results can under-
mine the ability of meta-analysts to accurately estimate a
summary treatment effect [1]. In particular, the non-
release of negative or non-significant results may lead to
the overestimation of the magnitude of a treatment ef-
fect and consequently to false conclusions about the
treatment’s efficacy (Figure 1).
For example, a systematic review by Jefferson et al. [2]
estimated that 60 percent of patient data from 10
Roche-conducted trials of oseltamivir (sold as ‘Tamiflu’)
remained unavailable to reviewers even after two years,Figure 1 Schematic illustration of the potential impact of unpublishe
demarcates an effect size showing no difference between treatment group
of the vertical line correspond to the intervention treatment group having
published studies found the intervention treatment to be significantly bett
indicated by having confidence intervals completely to the right of the ver
published studies. If we then include results from unpublished studies in th
change? The three diamonds at the bottom of the figure each represent a
and unpublished).despite repeated requests for the data [3]. This high per-
centage of unavailable information is clearly inadequate
for making robust conclusions about the efficacy and the
risks of using the drug.
Recent developments to mitigate publication bias due
to the non-publication of studies include i) the forma-
tion of public clinical trial registries for the prospective
registration of clinical trials, such as ClinicalTrials.gov in
the USA and ClinicalTrialsRegister.eu in the European
Union, ii) the adoption of a policy by the International
Committee of Medical Journal Editors (ICMJE) in 2005
that the journals they oversee would only publish results
of clinical trials which have been prospectively registered
in a public registry [4], and iii) the passage of the Food
and Drug Administration Amendments Act (FDAAA) of
2007 which expanded the requirements for the registry
of clinical trials that receive USA federal funding. Thesed studies on a meta-analytic summary effect. The vertical line
s for the outcome being studied. In this case, effect sizes to the right
more favorable outcomes than the control treatment group; all four
er than the control treatment with respect to the study outcome, as
tical line. The first diamond shows the pooled estimate across the four
e meta-analysis, how might the conclusion of the meta-analysis
possible outcome of the pooled estimate across all studies (published
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and proportion of clinical trials that are prospectively
registered [5]. However, researchers are not necessarily
obligated to release to the public the results of such tri-
als. Ross et al. [6] found that in a sample of NIH-funded
trials registered with ClinicalTrials.gov, less than half
were published within 30 months of trial completion.
Thus, while systematic reviewers may be aware of trials
that have been conducted and have details regarding
trial methodologies and sample sizes, they may not have
timely access to the results to include them in a meta-
analysis.
Our goal was to design and program a pragmatic ex-
ploratory tool for the systematic reviewer who wishes to
visualize the sensitivity of a meta-analytic summary to
the addition of one or more registered, unpublished
studies (RUSTs). We wanted our software to be open
source, easy to use, and with output easy to understand.
Our result, which we introduce in this paper, is the R
package Sensitivity Analysis of a Meta-analysis with
Unpublished but Registered Analytical Investigations
(SAMURAI).
Statistical methods used for gauging the potential im-
pact of publication bias, such as the trim and fill method
[7] and the Copas selection model [8], already exist. As
far as we know, however, no existing method uses the
information available in clinical trial registries to con-
duct the sensitivity of a meta-analytic summary effect to
RUSTs. Therefore, we believe that SAMURAI can be a
useful addition to the systematic reviewer’s toolkit.Methods
Assumptions
In developing the software application, we assumed the
following:
i) The meta-analysis consists of randomized clinical
trials, all addressing the same research question and
each with two independent intervention arms; an experi-
mental arm and a control arm. ii) For each RUST, the
clinical trial registry has information on the sample sizes
of both treatment arms. iii) Effect rates in the control
arms of RUSTs are the same as the pooled event rate
across control arms of all published studies in the meta-
analysis. iv) Any variation among studies is adequately
accounted for by random effects models; no additional
information on covariates is necessary in order to ex-
plain this variation.
We make no assumptions about the effect size of the
experimental arms of RUSTs. Instead, we leave it up to
the end-user to decide the anticipated effect size and dir-
ection of each RUST. In essence, with our methodology,
the end-user acquires the added flexibility and responsi-
bility of predicting anticipated effect sizes and directions.Description of algorithm for the computer software
The software requires that all published studies in the
meta-analytic dataset report their results in a similar for-
mat. Either all the studies have binary outcomes or all
the studies have continuous outcomes. Studies with bin-
ary outcomes should report 2 × 2 tables. Studies with
continuous outcomes should all report their results as
either i) the mean effect size and its standard deviation
within each treatment arm, or ii) the standardized mean
difference.
The dataset should also have the sample sizes of both
treatment arms for every study, including RUSTs. Entries
in ClinicalTrials.gov typically indicate total sample size
but not sample sizes for each treatment arm. We recom-
mend simply assuming a 1:1 allocation ratio between the
two treatment arms, unless the entry specifies a different
allocation ratio.
The end-user assigns each RUST an ‘outlook’ specify-
ing the size and direction of the effect. The end-user can
choose outlooks from a list of predefined options ran-
ging from ‘very positive’, for which the RUST is antici-
pated to heavily favor the experimental intervention, to
‘very negative’, for which the RUST is anticipated to
heavily favor the control intervention.
We defined ten such outlooks for RUSTs. For five of
these outlooks, the summary effect is associated with a
fixed number (which is preset to a default value but can
be adjusted by the end-user), whereas the other five out-
looks are based on the summary effect across the pub-
lished studies or its confidence interval.
With binary-outcome studies, SAMURAI will impute
the relative risk of each RUST according to the outlook
assigned to it by the end-user (Table 1). With studies
having continuous outcomes in the form of means and
standard deviations for each arm, the data are converted
to standardized mean differences (SMD). For each
RUST, SAMURAI will impute a SMD according to the
outlook assigned to it by the end-user (Table 2).
In addition, SAMURAI will impute the variance of the
SMD of a RUST using Borenstein’s ad-hoc ‘very good’
approximation [9]. We chose Borenstein’s approximation
as a matter of convenience, since it requires only the
sample sizes of the treatment arms in the unpublished
studies and the summary SMD across the published
studies, thereby bypassing the need to impute variances
for each treatment arm of a RUST.
Based on the end-user’s outlook selection for a RUST,
the software imputes an effect size and confidence inter-
val for that RUST, using the predefined effect size associ-
ated with that outlook, along with random noise thrown
in to mirror uncertainty in the estimate of the non-
published effect size. Once the effect sizes and confi-
dence intervals of the RUST are imputed, the software
calculates a summary effect using standard meta-analysis
Table 1 Default risk ratios (RR) assigned to unpublished studies with binary outcomes
Outlook Depends on published studies? If the outcome event is desired
(higher.is.better = T)
If the outcome event is undesired
(higher.is.better = F)
‘very positive’ No 3 0.33
‘positive’ 2 0.5
‘no effect’ 1 1
‘negative’ 0.5 2
‘very negative’ 0.33 3
‘very positive CL’ Yes, depends on CL of published studies UCLpub,1-α LCLpub,1-α
‘positive CL’ 0:5 bRRpub þ UCLpub;1a  0:5 bRRpub þ LCLpub;1a 
‘current effect’ bRRpub bRRpub
‘negative CL’ 0:5 bRRpub þ LCLpub;1−a  0:5 bRRpub þ UCLpub;1−a 
‘very negative CL’ LCLpub,1-α UCLpub,1-α
Note: ‘Positive’ outlooks favor the experimental treatment arm and ‘negative’ outlooks favor the control treatment arm.
RR: Risk ratio, or relative risk.
LCL: Lower confidence limit.
UCL: Upper confidence limit.cRRpub : The summary RR across all published studies.
LCLpub,1-α,UCLpub,1-α: The 1-α confidence interval of cRRpub .
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fects model using the popular inverse-variance method
by DerSimonian and Laird [10]. More mathematical de-
tails can be found in Additional file 1, which contains
pseudo-algorithmic descriptions of the methodology
used by SAMURAI.
We opted to use a random effects model since it al-
lows statistical inferences to be made about studies other
than those in the meta-analysis. In contrast, statistical
inferences made using a fixed-effects model are limited
to the studies in the meta-analysis [11].
The software outputs the results as forest plots. Each
forest plot includes a summary effect across just the pub-
lished studies, a summary effect across just the unpublishedTable 2 Default standardized mean differences (SMD) assigne
Outlook Depends on published studies? If th
‘very positive’ No
‘positive’
‘no effect’
‘negative’
‘very negative’
‘very positive CL’ Yes, depends on CL of published studies
‘positive CL’ 0
‘current effect’
‘negative CL’
‘very negative CL’
Note: ‘Positive’ outlooks favor the experimental treatment arm and ‘negative’ outloo
SMD: Standardized mean difference.
LCL: Lower confidence limit.
UCL: Upper confidence limit.dSMDpub : The summary SMD across all published studies.
(LCLpub,1-α, UCLpub,1-a): The 1-α confidence interval of dSMDpub .studies (whose outlooks are chosen by the end-user), and a
summary effect across all the studies, published and unpub-
lished, along with the between-study variance τ2.
Software
We developed our software as an R package instead of
as a spreadsheet program for the following reasons: i) R
is a widely used and freely available language for statis-
tical computing, and ii) R can produce better-looking
and more consistent graphics than a spreadsheet pro-
gram. In addition, R can readily be used to export graph-
ics to an Adobe Portable Document Format (PDF) file.
Learning to use R may be more difficult than learning
how to use a spreadsheet program; however, there are ad to unpublished studies with continuous outcomes
e outcome event is desired
(higher.is.better = T)
If the outcome event is undesired
(higher.is.better = F)
0.8 −0.8
0.3 −0.3
0 0
−0.3 0.3
−0.8 0.8
UCL,pub,1-α LCL,pub,1-α
:5 dSMDpub þ UCLpub;1−α  0:5 dSMDpub þ LCLpub;1−α 
dSMDpub dSMDpub
0:5 dSMDpub þ LCLpub;1−α  0:5 dSMDpub þ UCLpub;1−α 
LCL,pub,1-α UCL,pub,1-α
ks favor the control treatment arm.
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hope that end-users unfamiliar with R will find the
worked examples in this article a helpful primer.
Results and worked examples
SAMURAI is available free of charge and it is open-
source. The program and code are freely available on the
Internet via the Comprehensive R Archive Network
(CRAN) at http://cran.r-project.org/web/packages/SAM-
URAI/index.html. SAMURAI employs functions in the
R package metafor [12].
Installing and running SAMURAI
The end-user will first need to install R on their com-
puter, available through CRAN at http://cran.r-project.
org. R is available for computers with Linux, Macintosh,
or Windows operating systems. Once the end-user has
installed R and can run R on their computer, they can
install SAMURAI with the following command:
> install.packages(‘SAMURAI’)
(Note that the caret > represents a prompt that is not
typed by the end-user.)
Then the end-user can begin using SAMURAI after
typing in the following command:
> library(SAMURAI)
Formatting of dataset files
End-users of SAMURAI will first need to prepare their
dataset as a comma separated value (CSV) file with spe-
cific column headings. This data file can be created in a
spreadsheet program such as the open source LibreOf-
fice Calc or Microsoft Office Excel, then imported into
R. Details can be found in Additional file 1.
Worked example 1: trials with binary outcomes
We consider a dataset of trials published from 1990 to
2001 comparing counts of non-healing of duodenal ulcer
in patients on ulcer-healing drug with H. pylori eradica-
tion treatment (experimental arm) versus counts of non-
healing in patients on ulcer-healing drug alone (control
arm). The example dataset consists of 33 published stud-
ies listed in a meta-analysis by Ford et al. [13] (Table 3).
For the purposes of illustration, we will pretend that a
subset of these studies were registered but never pub-
lished, i.e., RUSTs. For each RUST, we remove informa-
tion on the number of events, but leave in the sample
sizes.
A version of the dataset is included in the SAMURAI
package as the dataset Hpylori, which differs from the
original dataset in Ford et al. [13] in that seven of the 33
studies are treated as unpublished. The end-user mayload and view this modified dataset by typing in the fol-
lowing commands at the R prompt:
> data(Hpylori)
> Hpylori
The second of these commands displays the dataset.
The sample sizes of the control and experimental arms
are in the columns labeled ctrl.n and expt.n,
respectively. The number of events in the control and
experimental arms are in the columns labeled ctrl.
events and expt.events, respectively.
To generate a forest plot (not shown) for the dataset,
we can give the following command:
> forestsens(table=Hpylori, binary=TRUE,
higher.is.better=FALSE, scale=0.8)
For reproducible results, one may freeze the random
variation by specifying a seed for the random number
generator, as in the following example:
> forestsens(table=Hpylori, binary=TRUE,
higher.is.better=FALSE, scale=0.8, random.
number.seed=106)
With random.number.seed=106 the summary
relative risk across all 33 studies is 0.64, with a 95% con-
fidence interval of (0.49, 0.82) (Figure not shown). End-
users may get slightly different results depending on
which, if any, random number seed they specify.
Since the outcome being measured is binary, we speci-
fied binary=TRUE. Furthermore, the events in the
dataset indicate the number of patients not healed; we
thereby specify higher.is.better=FALSE. Specify-
ing the scale parameter is optional, but in this case
helps our plot look neater by reducing font sizes to 80%
of the default font size.
Suppose we want to modify the outlooks of all unpub-
lished studies to, say, ‘very negative’. We can do this with
the following command:
> forestsens(table=Hpylori, binary=TRUE,
higher.is.better=FALSE, scale=0.8, random.
number.seed=106, outlook=‘very negative’)
In order to illustrate how an end-user would actually
examine the effect of RUSTs and their assumptions of out-
looks on the summary effect size, Figure 2 presents the
forest plot output from SAMURAI when the last seven
studies are considered as RUSTs and the outlook chosen
for the ‘unpublished’ studies is ‘very negative’. We see that
the effect size now does not significantly differ from 1.
Table 3 The dataset Hpylori, which is included in the R package SAMURAI
Study number Study name Year Outlook expt.events expt.n ctrl.events ctrl.n
1 Rauws 1990 published 7 24 5 26
2 Graham 1991 published 4 53 10 52
3 Bayrerdorffer 1992 published 2 29 4 29
4 Hosking 1992 published 8 78 21 77
5 Bianchi Porro 1993 published 7 91 12 92
6 Hentschel 1993 published 1 52 3 52
7 Mantzaris 1993 published 5 17 8 16
8 Wang 1993 published 3 23 6 36
9 Lin 1994 published 0 21 2 21
10 Spinzi 1994 published 2 24 3 29
11 Bayrerdorffer 1995 published 4 136 12 128
12 Katoh 1995 published 0 27 1 25
13 Logan 1995 published 2 70 6 78
14 Pinero 1995 published 8 30 7 30
15 Sobhani 1995 published 7 59 15 60
16 Avsar 1996 published 2 23 10 22
17 Figueroa 1996 published 4 57 4 43
18 Harford 1996 published 36 127 25 69
19 Kato 1996 published 0 28 1 23
20 O'Morain 1996 published 9 102 15 106
21 Parente 1996 published 7 63 1 33
22 Porro 1996 published 2 17 9 15
23 Shirotani 1996 published 4 25 6 25
24 Bardhan 1997 published 4 141 6 74
25 Carpintero 1997 published 3 78 3 44
26 Pounder 1997 published 5 61 8 30
27 Graham 1998 negative NA 77 NA 76
28 Schwartz 1998 positive NA 292 NA 60
29 Kepecki 1999 negative NA 39 NA 34
30 van Zanten 1999 very positive NA 98 NA 48
31 Wong 1999 negative NA 57 NA 57
32 Asaka 2001 positive NA 205 NA 51
33 Mones 2001 positive NA 42 NA 43
expt.n: Sample size of the experimental treatment arm.
ctrl.n: Sample size of the control/reference treatment arm.
expt.events: Number of events occurring within the experimental treatment group.
ctrl.events: Number of events occurring within the control/reference treatment group.
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lished studies have values that are close to but not
exactly 3, which is the relative risk value assigned to
‘very negative’ studies with binary events for ‘bad’ out-
come variables.
As a sensitivity analysis, we compare the summary
effect sizes and their 95% confidence intervals under
different scenarios. For the purposes of illustration,
we pretend that varying subsets of these studies wereregistered but never published; using the original dataset
in Ford et al. [13], we set studies published from 1995
onwards as RUSTs and incrementally consider as pub-
lished the studies in subsequent years, until reaching
2001. We then create a sensitivity plot of effect sizes as
more studies are considered published. We examine the
scenarios under which all RUSTs are assigned the same
outlook, ranging from ‘very positive’ to ‘very negative’.
Figure 3 displays the variation in the estimated effect sizes
Figure 2 Forest plot for the dataset Hpyloris with all seven unpublished studies assigned ‘very negative’ outcomes. The dataset has
33 published studies. The random number seed used to generate this figure was 106.
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Figure 3 Sensitivity analysis using the dataset Hpylori. This figure shows the estimated summary effect sizes for the dataset Hpylori
with corresponding 95% confidence intervals, as the number of unpublished studies is diminished and with all RUSTs having the same outlook,
ranging from ‘very positive’ to ‘very negative’. This figure was prepared with the R package ggplot2.
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or not.
One can generate a forest plot for each of the ten out-
looks by specifying the option all.outlooks=TRUE,
which will assign the same outlook to all RUSTs:
> forestsens(table=Hpylori, binary=TRUE,
higher.is.better=FALSE, scale=0.8, random.
number.seed=106, all.outlooks=TRUE)
We can put all of these plots into a single PDF file (in
this case with the name filename.pdf ) with the fol-
lowing commands:
> pdf(‘filename.pdf’)
> forestsens(table=Hpylori, binary=TRUE,
higher.is.better=FALSE, scale=0.8, random.
number.seed=106, all.outlooks=TRUE)
> dev.off()
When the parameter all.outlooks=TRUE is spe-
cified, the function forestsens also generates a
table of overall summary effects, their confidence in-
tervals (from the lower confidence limit lcl to the
upper confidence limit ucl), and an estimate of τ2
(tau2), which is a measure of heterogeneity between
studies.
The forestsens function allows the end-user to
override the default relative risk assigned to any outlook.
For example, if we want to change the relative risks of
‘very negative’ studies from the default of 3 to 2.5, and toTable 4 Summary effects for the Hpylori dataset after all un
Scenario
number
Outlook assigned to all 7
unpublished studies
Relative risk (RR) assigned to
unpublished studies
1 very positive 0.33
2 positive 0.5
3 no effect 1
4 negative 2
4a* negative 1.5
5 very negative 3
5a* very negative 2.5
6 very positive CL LCLpub,1-α
7 positive CL 0:5 bRRpub þ LCLpub;1−α 
8 current effect bRRpub
9 negative CL 0:5 bRRpub þ UCLpub;1−α 
10 very negative CL UCLpub,1-α
(The random number seed used to generate this table was 106.)
*In these cases all unpublished studies were assigned an RR different from the defa
**A displayed value of ‘0’ for ‘tau2’ indicates a τ2 value less than 0.001.change the relative risks of ‘negative’ studies from 2 to
1.5, we can do so as follows:
> forestsens(table=Hpylori, binary=TRUE,
higher.is.better=FALSE, scale=0.8, random.
number.seed=106, all.outlooks=TRUE, rr.
neg=1.5, rr.vneg=2.5)
The results are included in Table 4.
Worked example 2: trials with continuous outcomes
A systematic review by Jurgens et al. [14] included a
meta-analysis of the effect of green tea consumption on
weight loss using 14 placebo-controlled randomized tri-
als published between 2004 and 2010.
Of these fourteen studies, we shall, for the purposes of
our example, arbitrarily treat the three studies published
from 2009 onward as RUSTs. Thus the dataset greentea,
included in the SAMURAI package, contains 11 published
studies and three RUSTs (Table 5). This dataset can be
loaded into memory and viewed by typing in the following
commands:
> data(greentea)
> greentea
The sample sizes of the control and experimental arms
are in the columns labeled ctrl.n and expt.n, re-
spectively. The mean weight loss in control and experi-
mental arms are in the columns labeled ctrl.mean
and expt.mean, respectively. Their respective standard
deviations are ctrl.sd and expt.sd.published studies assigned the same default outlook
all Summary
effect (RR)
Lower 95%
confidence limit
Upper 95%
confidence limit
τ2**
0.518 0.432 0.621 <0.001
0.561 0.471 0.669 <0.001
0.697 0.585 0.829 0.011
0.801 0.609 1.052 0.317
0.759 0.602 0.958 0.166
0.866 0.616 1.217 0.636
0.841 0.614 1.151 0.501
0.546 0.457 0.652 <0.001
0.573 0.481 0.682 <0.001
0.591 0.497 0.703 <0.001
0.603 0.507 0.716 <0.001
0.634 0.534 0.752 <0.001
ult RR.
Table 5 The dataset greentea, which is included in the R package SAMURAI
Study number Study name Year Outlook expt.mean expt.sd expt.n ctrl.mean ctrl.sd ctrl.n
1 Kataoka 2004 published −1.3 1.7 71 −0.8 1.7 71
2 Takashima 2004 published −1.6 1.9 10 −1.4 1.5 9
3 Diepvens 2005 published −4.21 2.7 23 −4.19 1.3 23
4 Kajimoto 2005 published −0.55 2.1 129 0.6 2 66
5 Kozuma 2005 published −2.7 1.5 107 0.8 0.9 119
6 Hill 2007 published 0.08 0.9 19 −0.45 1.2 19
7 Nagao 2007 published −1.7 1.5 123 −0.1 1.7 117
8 Auvichayapat 2008 published −2.7 2.2 30 −2 9.7 30
9 Hsu 2008 published −0.15 2 41 −0.03 1.9 37
10 Takase 2008 published −2.9 1.2 44 0.1 0.7 45
11 Takeshita 2008 published −1.1 1.3 40 −0.3 1.5 41
12 Maki 2009 positive NA NA 65 NA NA 63
13 Suzuki 2009 no effect NA NA 18 NA NA 20
14 Wang 2010 no effect NA NA 139 NA NA 43
expt.n: Sample size of the experimental treatment arm.
ctrl.n: Sample size of the control/reference treatment arm.
expt.mean: Mean effect size within the experimental treatment group.
ctrl.mean: Mean effect size within the control/reference treatment group.
expt.sd: Standard deviation of effect size within the experimental treatment group.
ctrl.mean: Standard deviation of effect size within the control/reference treatment group.
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following command:
> forestsens(greentea, binary=FALSE, mean.
sd=TRUE, higher.is.better=FALSE)
Since the outcome being measured is continuous (and
hence not binary), we specified binary=FALSE. Fur-
thermore, since the outcome data are in the form of
means and standard deviations, we specify mean.
sd=TRUE.
In this example, a more negative change in weight is
desired. That is to say, we desire that the weight (out-
come) in the experimental arm will be lower than the
weight (outcome) in the control arm. When a lower out-
come is desired, as in this case, choose the option
higher.is.better=FALSE (conversely, if a higher
outcome is desired, choose the option higher.is.
better=TRUE).
Again, to make these results reproducible, we can spe-
cify a random.number.seed with any integer, as in
the following example:
> forestsens(greentea, binary=FALSE, mean.
sd=TRUE, higher.is.better=FALSE, random.
number.seed=52)
Suppose we want to modify the outlooks of all unpub-
lished studies to, say, ‘negative’. We can do this with the
following command:> forestsens(greentea, binary=FALSE,
mean.sd=TRUE, higher.is.better=FALSE,ran-
dom.number.seed=52,outlook=‘negative’)
Note that in Figure 4, the SMD for each unpublished
study is close to but not exactly 0.3, which is the SMD
assigned to ‘negative’ studies when a lower outcome is
preferable.
As a sensitivity analysis, we compare the summary
effect sizes and their 95% confidence intervals under
different scenarios. As was done for the Hpylori data-
set in Worked Example 1 (Figure 3), we pretend that
varying subsets of the studies in the greentea dataset
were registered but never published; using the original
dataset in Jurgens et al. [14], we set studies published
from 2006 onwards as RUSTs and incrementally con-
sider as published the studies in subsequent years, until
reaching 2010. We then create a sensitivity plot of ef-
fect sizes as more studies are considered published.
We examine the scenarios under which all RUSTs are
assigned the same outlook, from ‘very positive’ to ‘very
negative’. Figure 5 displays the variation in the estimated
effect sizes as studies from 2006 onwards are considered
published or not.
We can generate a forest plot for each of the ten outlooks
in Table 2 with the option all.outlooks=TRUE.
> forestsens(greentea, binary=FALSE, mean.
sd=TRUE, higher.is.better=FALSE, random.
number.seed=52, all.outlooks=TRUE)
−1.0
−0.5
0.0
0.5
2006
(5/9)
2007
(7/7)
2008
(11/3)
2009
(13/1)
2010
(14/0)
Year (# published / # RUSTs)
St
an
da
rd
ize
d 
m
ea
n 
di
ffe
re
n
ce
outlook
very negative
negative
no effect
positive
very positive
Figure 5 Sensitivity analysis using the dataset greentea. The figure shows the estimated summary effect sizes for the dataset greentea
with corresponding 95% confidence intervals, as the number of unpublished studies is diminished and with all RUSTs having the same outlook,
ranging from ‘very positive’ to ‘very negative’ This figure was prepared with the R package ggplot2.
Figure 4 Forest plot for the dataset greentea with all three unpublished studies assigned to have ‘negative’ outcomes. The dataset
has 11 published studies. The random number seed used to generate this figure was 52.
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their confidence intervals (from the lower confidence
limit lcl to the upper confidence limit ucl), and an es-
timate of τ2 (tau2), which is a measure of heterogeneity
between studies (Table 6).Results and discussion
Discussion of worked examples
The sensitivity analyses in the worked examples indicate
that successful approximation of the actual summary ef-
fect depends on i) which outlooks the end-user selects
(Tables 4 and 6) and ii) the ratio of number of published
studies to RUSTs (Figures 3 and 5).
Figures 3 and 5 in the worked examples illustrate how
close the estimated summary effect may come to the ac-
tual summary effect. This accuracy, however, depends
largely on the end-user’s success in predicting the out-
comes of registered, unpublished studies. As with any
software, the ‘garbage in, garbage out’ principle applies
to the use of SAMURAI. The end-user has the flexibility
of choosing anticipated effect sizes and directions but
also thereby assumes the burden of responsibility for
making these choices.Worked Example 1
By the year 2001, all 33 studies in the original dataset
compiled by Ford et al. [13] had been published. As de-
termined by the DerSimonian-Laird method, the sum-
mary relative risk was 0.66, and its 95% confidence
interval was (0.58, 0.76) (Figure 3). The relative risk and
its confidence interval are below 1.0, indicating that the
proportion of patients not healed by the experimental
intervention was lower than the proportion of patients
not healed by the control intervention (recall that the
events counted in this dataset represent numbers of pa-
tients not healed). Thus, the summary relative risk favors
the experimental treatment.Table 6 Summary effects for the greentea dataset after all un
Scenario
number
Outlook assigned to all 3
unpublished studies
Standardized mean difference
assigned to all unpublished s
1 very positive −0.8
2 positive −0.3
3 no effect 0
4 negative 0.3
5 very negative 0.8
6 very positive CL LCLpub,1-α
7 positive CL 0:5 dSMDpubþ LCLpub;1−α 
8 current dSMDpub
9 negative CL 0:5 dSMDpubþ UCLpub;1−α 
10 very negative CL UCLpub,1-α
The random number seed used to generate this table was 52.Now, suppose it is the year 1998, when five of the
studies remain unpublished. Table 4 shows that treating
all studies published on or after 1998 as RUSTs with a
‘negative’ or ‘very negative’ outlook leads to an overall
summary effect with a confidence interval that straddles
a relative risk of 1.0, which corresponds to having no
statistically significant difference between the two treat-
ment arms beyond a 0.05 level. After changing the rela-
tive risk for a ‘negative’ study from the default value of 2
to 1.5, we see that having all unpublished studies with a
‘negative’ outlook no longer straddles a relative risk of
1.0. Thus, we see that the summary effect size is sensi-
tive to the outlooks chosen by the end-user.
We can also see in Figure 3, that choosing a ‘very nega-
tive’ outlook would have suggested the non-significance of
a treatment effect as early as 1998. Similarly, choosing a
‘negative’ outlook for all RUSTs would have suggested the
non-significance of the treatment effect as early as 1997,
when seven of the studies were unpublished.
Now suppose it is the year 1995, when 15 of these studies
have been published while 18 studies yet remain as RUSTs,
registered but unpublished. If we then choose to assign
these 18 RUSTs the outlook ‘very negative’, then the sum-
mary relative risk and its 95% confidence interval would be
above 1.0, thereby favoring the control intervention (as the
proportion of patients not healed by the experimental inter-
vention would exceed the proportion of patients not healed
by the control intervention). If we instead elected to assign
all 18 RUSTs the outlook ‘negative’, then the 95% confi-
dence interval of the summary relative risk would straddle
1.0, suggesting there would be no statistically significant dif-
ference between the control and the experimental interven-
tions. On the other hand, had we chosen ‘no effect’,
‘positive’, or ‘very positive’, then the summary relative risk
and its 95% confidence interval would still be below 1.0,
thereby favoring the experimental intervention. Thus, we
see that the summary effect size is also sensitive to the ratio
of published studies to RUSTs.published studies assigned the same outlook
(SMD)
tudies
Summary
effect
Lower 95%
confidence limit
Upper 95%
confidence limit
τ2
−0.411 −1.013 0.192 1.256
−0.519 −1.057 0.019 0.991
−0.586 −1.092 −0.080 0.868
−0.651 −1.135 −0.166 0.791
−0.759 −1.230 −0.287 0.744
−0.877 −1.368 −0.386 0.810
−0.814 −1.290 −0.338 0.761
−0.748 −1.219 −0.277 0.744
−0.681 −1.159 −0.204 0.767
−0.614 −1.110 −0.119 0.830
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The summary treatment effect calculated for the original
dataset compiled by Jurgens et al. [14] is –0.61, with a 95%
confidence interval of (–1.10, –0.11). A standardized mean
difference of zero corresponds to having no detectable dif-
ference between treatments. This result suggests that par-
ticipants in the experimental arm lost more weight than
participants in the control arm.
Table 6 shows that treating all studies published on or
after 2009 as RUSTs with a ‘very positive’ or ‘positive’ out-
look leads to an overall summary effect with a confidence
interval that straddles an SMD of 0.0, which corresponds to
having no statistically significant difference between the
two intervention arms. In contrast, choosing any of the
other eight outlooks does not result in a confidence interval
that straddles 0.0. Thus, we see that the summary effect size
is sensitive to the outlooks chosen by the end-user.
In Figure 5, we can see that successful approximation of
the actual summary effect depends on which outlooks the
end selects and on the ratio of number of published studies
to RUSTs. Choosing a ‘very negative’ or ‘negative’ outlook
would have suggested a statistically significant treatment ef-
fect until 2009, when only one RUST was left. Choosing a
‘no effect’ outlook would not have suggested a statistically
significant treatment effect until 2008 when three RUSTs
remained. In contrast, choosing a ‘positive’ or ‘very positive’
outlook would have suggested a statistically significant
treatment effect at least as early as 2006.
Comparison with existing methods and software
Out of all his numerous press conferences after 9/11,
perhaps the best known quote by former US Secretary
of Defense Donald Rumsfeld was this Socratic idea:
“There are known knowns; there are things we know we
know. We also know there are known unknowns; that is
to say, we know there are some things we don’t know.
But there are also unknown unknowns; the ones we
don’t know we don’t know.”
Prior to the establishment of clinical trial registries,
assessing the impact of unpublished studies on a meta-
analysis has entailed making broad assumptions about
the distribution of ‘unknown unknowns’. The trim and
fill method by Duval & Tweedie [7] works under the as-
sumption that the distribution of all effect sizes, published
and unpublished, is symmetrical around the true mean.
Selection models, such as the Copas selection model [8],
assume that publication is conditionally dependent on ef-
fect size, i.e., the data is assumed to be missing at random.
The establishment of clinical trial registries now hold
the promise of reducing the proportion of ‘unknown un-
known’ effect sizes determined by unpublished studies
and increasing the proportion of ‘known unknown’
effect sizes determined by RUSTs. However, this ideal is
far from the current reality, for laws and regulationshave not been thorough enough to ensure full and
timely disclosure of completed trial results.
Discrepancies in reporting standards have allowed report-
ing bias to continue. Some data elements required by the
ICMJE are optional for ClinicalTrials.gov and for the
FDAAA of 2007, including study completion date and
reasons why a study was stopped [15]. Also, the ICMJE
requires registration prior to enrollment of the first partici-
pant, while ClinicalTrials.gov allows registration ‘at any
time’, even after study completion. Ross et al. [16] found
that out of a sample of registered trials completed prior to
2004, only 60% had their results published within 4 years.
Mathieu et al. [17] found prevalence of selective reporting
among adequately registered published studies, as evi-
denced by discrepancies between study outcomes registered
and study outcomes published in 31% of those studies.
Furthermore, the increasing number of clinical trials
being conducted outside of the US contributes to re-
trieval bias. FDAAA 801 only applies to ‘applicable clin-
ical trials’, including trials with at least one site in the
US. As clinical trials are increasingly held overseas, it is
unclear how quickly the laws of other nations will catch
up and require sufficient registration of these as well.
The Trial and Experimental Studies Transparency Act of
2012 was introduced to the US Congress in May 2012
for the purpose of closing loopholes in the FDAAA; as
of December 2013, it remains in committee, not having
yet been approved for a vote on the House floor.
In the current landscape of clinical trial registries with
its mix of ‘known unknowns’ and ‘unknown unknowns’,
modeling may become too complicated to implement.
Copas notes the limitations of selection models: “[P]ubli-
cation may depend on study size as well as many other
features of the study’s design and outcome. However, at-
tempts to fit more complicated selection models seem
problematical, since when the number of studies is small
(as is often the case in practice) the information in the
data is very limited. No model will reflect all the reasons
why some papers are selected and some are not” [18].
We have designed SAMURAI to incorporate enroll-
ment information (required by FDAAA), but have for-
gone the theoretical rigor of previously existing methods
in order to pursue the pragmatic goal of developing an
exploratory tool for systematic reviewers (including non-
statisticians) wishing to illustrate the potential, if not
necessarily the most probable, impact of ‘known un-
known’ RUSTs on a meta-analytic summary effect. That
is, SAMURAI does not on its own conduct a probabilis-
tic sensitivity analysis, but rather, it produces output that
could be used in, say, a ‘best-case, worst-case’ analysis.
As far as we know, there exists no other software
that allows the end-user to include sample sizes of
unpublished studies. However, we have largely left it
up to the systematic reviewer as to how to address
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trial registries.
We have designed SAMURAI on the premise that the
requirements by the ICJME will eventually be incorpo-
rated into law. Thus we make the following assumptions:
i) all studies will be registered before commencement; ii)
all registered studies are easily accessible to the system-
atic reviewers; and iii) all results found by registered
studies will be released in a timely manner. We thereby
encourage systematic reviewers to use SAMURAI to
make interim meta-analyses but not for drawing final
conclusions. As noted by Deborah Zarin, director of
ClinicalTrials.gov, “[J]ournals will continue to add value
by publishing useful and readable trial reports that clini-
cians, the media, and patients can interpret and use…
[T]he results disclosed for the FDA will not have been
externally peer reviewed and will be preliminary” [19].
While the default methodology of SAMURAI is ad
hoc, SAMURAI also allows end-users to impute effect
sizes with values of their choosing rather than with the
default values. The end-user may elect to use a model
with assumptions about ‘unknown unknowns’ to gener-
ate these values; in so doing the end-user should be
knowledgeable of the assumptions associated of that
model.
While we hope that the consideration of RUSTs
will, in the long term, sufficiently address publication
bias, we acknowledge that the current reality is far
from ideal. And while our approach leaves much of
the burden of imputation up to the systematic reviewer,
we hope that this burden will be lifted by regulations
requiring more transparency on the part of study
investigators.
No matter what approach is taken, the systematic re-
viewer should keep in mind that “high quality syntheses
require considerably more than just the application of
quantitative procedures” [16]. It is still incumbent upon
systematic reviewers to examine clinical trials for other
kinds of biases, such as trial designs that rig experi-
mental treatment dosages to be much larger than
control treatment dosages [20]. Thus, the estimates of
confidence intervals presented in forest plots generated
using SAMURAI should be regarded with some cau-
tion. As Copas notes, “If we see the aim of sensitivity
analysis in terms of an informal warning of how sen-
sitively the conclusions from a meta-analysis can de-
pend on selection, then, arguably, the numerical
accuracy of these intervals for specific values of P <1
is not particularly important” [18]. After all, ‘known
unknowns’ are still unknowns.
Assumptions and limitations
Pigott differentiates between the following types of miss-
ing data: missing studies, missing effect sizes, and missingcovariates [21]. SAMURAI handles missing effect sizes
under the premise that all relevant missing studies have
been identified. SAMURAI does not handle missing co-
variates, but rather assumes that a random effects model
without covariates adequately accounts for variation be-
tween studies.
Some additional assumptions were listed in the Methods
section. As a result, the justification or utility of the use of
SAMURAI may be weakened in cases where i) there exist a
large number of unpublished and unregistered trials, ii)
event rates of control arms of unpublished studies with bin-
ary outcomes may be substantially different from the event
rate across the control arms of published studies, or iii) het-
erogeneity among studies is severe enough to question
whether stratification of studies would be more appropriate
(an easy workaround for severe heterogeneity, however,
may be to compute a summary effect for each strata).
DerSimonian and Kacker [22] have proposed alterna-
tive random effects modeling approaches as improve-
ments upon the commonly used DerSimonian-Laird
method. Future software could implement the more
complex but less widespread methods they proposed.
Conclusions
With the increase in the number of registered clinical
trials, systematic reviewers are now more likely to ac-
quire evidence of the existence of unpublished studies.
However, they have not yet had a statistical approach to
incorporate this information into quantitative analyses.
SAMURAI could prove a useful tool for reviewers to in-
tegrate information from unpublished studies to assess
the potential impact of publication bias on the results of
meta-analyses.
Availability and requirements
Project name: SAMURAI
Project home page: http://cran.r-project.org/web/pack-
ages/SAMURAI/index.html
Operating system(s): Platform independent
Programming language: R
License: GNU GPL 2 or 3
Package installation
We have written SAMURAI as an R package, and have
made the SAMURAI package available free of charge
under an open source General Public License (GPL).
Users of SAMURAI will also need to install and load the
existing R package metafor [11].
Using R GUI or RStudio, one can install these pack-
ages with the following commands:
> install.packages(‘metafor’)
> install.packages(‘SAMURAI’)
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metafor packages from the Comprehensive R Archive
Network (CRAN) at the following websites:
http://cran.r-project.org/web/packages/SAMURAI/
index.html,
http://cran.r-project.org/web/packages/metafor/index.
html.
Additional file
Additional file 1: Technical Appendix for the R Package SAMURAI.
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